S1GE34 Stock Overview
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Seagen Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$56.70 |
52 Week High | US$56.70 |
52 Week Low | US$33.10 |
Beta | 0.32 |
1 Month Change | 5.49% |
3 Month Change | 12.28% |
1 Year Change | n/a |
3 Year Change | 13.65% |
5 Year Change | n/a |
Change since IPO | -3.54% |
Recent News & Updates
Recent updates
Shareholder Returns
S1GE34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | 6.7% | -3.0% | -1.0% |
1Y | n/a | -9.0% | 13.1% |
Return vs Industry: Insufficient data to determine how S1GE34 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how S1GE34 performed against the BR Market.
Price Volatility
S1GE34 volatility | |
---|---|
S1GE34 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.4% |
Market Average Movement | 4.6% |
10% most volatile stocks in BR Market | 8.7% |
10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: S1GE34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine S1GE34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 3,256 | David Epstein | www.seagen.com |
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Seagen Inc. Fundamentals Summary
S1GE34 fundamental statistics | |
---|---|
Market cap | R$211.92b |
Earnings (TTM) | -R$3.68b |
Revenue (TTM) | R$11.30b |
18.8x
P/S Ratio-57.5x
P/E RatioIs S1GE34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
S1GE34 income statement (TTM) | |
---|---|
Revenue | US$2.30b |
Cost of Revenue | US$2.13b |
Gross Profit | US$171.59m |
Other Expenses | US$921.81m |
Earnings | -US$750.22m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.98 |
Gross Margin | 7.46% |
Net Profit Margin | -32.61% |
Debt/Equity Ratio | 0% |
How did S1GE34 perform over the long term?
See historical performance and comparison